Differential expression of HSP70 and ultrastructure of heart and liver tissues of rats treated with adriamycin: protective role of L-carnitine.

Mirian Strauss and Noraidys Porras.

Sección de Biología Celular, Instituto de Medicina Tropical, Universidad Central de Venezuela. Apartado Postal 47019, Caracas 1041-A, Venezuela. E-mail: mstraussve@yahoo.com

Abstract. The anticancer drug adriamycin has been associated to tissular oxidative stress. In this regard, the promotion of anti-stress protein synthesis by L-carnitine has been suggested in rat adriamycin-induced cardiomyopathy in the long-term. However, the citoprotective role of L-carnitine in cardiac and hepatic tissues after short-term adriamycin treatment is unknown. HSP70 in the supernatant of the homogenized cardiac and hepatic tissues after short-term adriamycin treatment was determined by Western blot analysis with and without L-carnitine protection and compared to the subcellular characteristics of both tissues by transmission electron microscopic analysis. Female Sprague-Dawley rats (n = 6), body weight 40-60g, were randomized into four groups: control, adriamycin, L-carnitine and L-carnitine-adriamycin. Saline, adriamycin (15 mg/kg body weight) and L-carnitine (20 mg before adriamycin) were given intravenously (0.1 mL). HSP70 accumulation was different between the control and the adriamycin samples of both tissues. HSP70 was higher in the liver than in the heart both with and without L-carnitine protection. The nuclei of heart cells, in the adriamycin group showed alterations including, form and irregular perinuclear cysternae with invaginations of different sizes that were not observed in the L-carnitine–adriamycin samples. Considering the differential expression of HSP70 between liver and heart, our results may be important for understanding the role of these proteins in the adriamycin-induced distinct levels of organ damage and dysfunction. We suggest that L-carnitine exogenous administration might enhance the relationship between the cellular energy state and the activation of heat shock response by an unknown mechanism. L-carnitine may enhance HSP70 in a cellular-type manner.

Key words: HSP70; ultrastructure; adriamycin; heart-liver; L-carnitine. 

Expresión diferencial de HSP70 y ultraestructura de tejido cardíaco y hepático de rata tratado con adriamicina: papel protectivo de la L-carnitina.

Resumen. La adriamicina, droga anticancerosa, ha sido asociada con el estrés oxidativo tisular. En este sentido, la promoción de la síntesis de proteínas anti-estrés por L-carnitina ha sido sugerida en las cardiomiopatías de largo plazo inducidas por adriamicina en ratas. Sin embargo, el papel citoprotectivo de la L-carnitina en tejido cardiaco y hepático, en la intoxicación por adriamicina en el corto plazo, se desconoce. La HSP70 presente en los sobrenadantes de homogenatos de tejido cardiaco y hepático luego de tratamiento con adriamicina a corto plazo y protección de L-carnitina, fue determinada mediante técnicas de Western blot y comparada con las características subcelulares de ambos tejidos. Ratas hembras Sprague Dawley (n = 6), de peso corporal entre 40-60g, fueron distribuidas aleatoriamente en cuatro grupos: control, adriamicina, L-carnitina y L-carnitina-adriamicina; recibiendo por vía intravenosa 0,1 mL de: solución salina, 15 mg/kg de peso corporal, 20 mg previo a la adriamicina y ambas, respectivamente. Se determinó una acumulación diferencial de la HSP70 entre las muestras del grupo control y adriamicina para ambos tejidos. La mayor acumulación de HSP70 fue en hígado, con y sin protección de L-carnitina. En el grupo adriamicina, las células cardiacas mostraron núcleos de forma no redondeada y cisterna perinuclear con invaginaciones de diferente tamaño, hallazgos que no fueron observados en las muestras del grupo protegido L-carnitina-adriamicina. Tomando en cuenta la expresión diferencial de HSP70 entre hígado y corazón, nuestros resultados pueden ser importantes para entender el papel de las proteínas de choque térmico contra los diferentes niveles de órgano toxicidad inducida por adriamicina. Se sugiere que la administración exógena de L-carnitina podría favorecer la relación entre el estado energético celular y la activación de la respuesta de choque térmico mediante un mecanismo desconocido y de una manera tejido dependiente.

Palabras clave: HSP70, ultraestructura, Adriamicina, corazón-hígado, L-carnitina.

Received: 09-11-2005. Accepted: 04-05-2006.

The widely used anticancer drug adriamycin (ADR) produces toxic effects in numerous organs, the most serious being heart damage. Heart toxicity in human patients is generally expressed as cardiomyopathy following chronic administration whereas the liver is relatively resistant to damage (1-3). ADR has been shown to be a potential source of free radicals. In in vitro studies, quinone-containing anticancer agents, including ADR, have been shown to form semiquinone free radical intermediates in the presence of certain flavin enzymes (4). ADR-induced changes in membrane functions have been shown to be accompanied by lipid peroxidation in in vitro as well as in vivo studies (5, 6). This increased peroxidation of polyunsaturated fatty acids is recognized as one of the possible biochemical mechanisms for the genesis of membrane injury in the myocardium (7). The role of ADR is associated to the flow of electrons from NADH to molecular oxygen and the production of free radicals. Interaction of ADR with cardiolipin, may contribute to the decline in cardiolipin-dependent enzymes such as coenzyme A and cytochrome oxidase (7, 8). The cardiovascular toxicity of ADR was attributed to a switch in the enzymatic activity of eNOS from a nitric oxide generating enzyme to a superoxide-generating enzyme (i.e. NADHP oxidase activity). In this sense, it have been demonstrated that heart tissue reveals depression in the activities of anti-oxidative enzymes, including catalase and dismutase superoxide (9). Hepatic levels of glutatione (GSH) and GSH peroxidases I and II have been shown to be relatively high and peroxidative damage to hepatocytes was obviated by GSH. In contrast to the liver, it has been demonstrated that the heart has extremely low activities of GSH peroxidase (10). In this regard, it is believed that constitutive cellular protection against acute stress is provided by a variety of intracellular components including the antioxidative enzymatic system, antioxidatives and perhaps heat shock proteins (HSPs) (11). The HSPs constitute a cellular system of endogenous protection which contributes for protein homeostasis and is essential for cellular viability (12). The over-expression of individual HSPs either in cultured cardiac cells in vitro or in the intact heart has a protective effect. In particular, HSP70 confers protection against cardiac ischemic damage and against a variety of adverse environmental conditions including certain anticancer drugs (13-17). The expression levels of HSP70 in cells correlated well with their survival following treatments with the tumor necrosis factor, staurosporine and ADR (18, 19). HSP70 rescues cells from apoptosis downstream of some known anti-apoptotic proteins such as caspase 3 (20, 21). However, HSP70 mRNA and protein are induced in different cell types depending on the severity, the nature of the stimulus and the biochemical characteristics of the tissue exposure to stress (22). An example of a cell-type specific stress response may be represented by the findings where rat liver samples showed the greatest accumulation of HSP72 after heat shock in comparison to other tissues including the heart (23). On the other hand, L-carnitine (L-Car), a derivative of natural amino acid and a metabolizing antioxidative agent, promotes fatty acid oxidation by translocating activated long-chain fatty acid into the matrix of mitochondria (24). L-Car has a cardio protective role against many toxic stresses including antimony (25), and promotes the accumulation of HSP25 as a short-term result of L-Car protective strategy, previous to ADR administration which is associated in the long term to alterations of much less severity (26). Nevertheless, it is not known whether there is a relationship between different heart and liver ADR subcellular toxic severity and different accumulation of HSP70 with and without the promotion of HSP70 by L-Car. Seeking to identify molecular clues regarding ADR-induced cardiotoxicity, the aim of this study was to analyse HSP70 response against morphological features in heart and liver of short-term ADR-treated rats. Moreover, given the potential protective role of L-Car against heart pathologies (26-28), we wonder about its relationship with HSP70 response. 

METHODS 

Animals: Female Sprague-Dawley rats (40-60 g), obtained from the Instituto Venezolano de Investigaciones Científicas (Caracas, Venezuela), were used. The rats were allowed free access to standard rodent chow and water ad libitum. The animals were maintained according to the norms specified in the “Guide to the Care and Use of Laboratory Animals” of the U.S. National Institute of Health (NIH publication No. 85-23, revised 1985). 

MATERIALS 

Sigma Company (Miami, USA) was the source of all biochemical compounds, monoclonal antibodies and ADR. L-Car was donated by Elmor Laboratories (Caracas, Venezuela). 

Experimental design 

The animals were randomized in four groups (n = 6): Control, ADR, L-Car and L-Car-ADR. The antitumoral drug was injected i.v. to an accumulated dose of 15 mg/kg body wt, divided into three subdoses of 5 mg/kg body wt (in 0.1 mL of sterile water) applied at 3-day intervals. Control rats received saline solution (0.1 mL). L-Car was administered i.v. at a dose of 20 mg (0.1 mL) before each ADR subdose. 24 hours after the third ADR subdose heart and liver were removed for subsequent biochemical and ultrastructural study. 

Western blots analysis 

Left ventricular free wall and central hepatic lobule samples were homogenized (4°C; 1 mL extraction buffer Tris-HCl 20mM, EDTA 2mM, PMFS 1mM, pH 7.4) using a Potter-Elevehjem tissue grinder. The HSP70 content in the supernatant of homogenized heart and hepatic tissue was determined by Western blot analysis (29). Protein samples were diluted with 4 x Laemmli buffer solution. Equal amounts of protein samples (5 µg per lane) were applied to 1mm thick, 10% polyacrylamide gels and separated by SDS-PAGE (30). The equivalence of loading concentrations and the adequacy of the sample preparation were confirmed by visualization of protein with Coomassie blue stain. Proteins were transferred to nitrocellulose membrane which were washed in PBS with 0.3% low-fat milk to block non-specific binding sites and incubated at 4°C with mouse monoclonal IgG cross-reactive with HSP70 in a 1:5000 dilution at room temperature for 90 min. The immunodetection included: blocking of protein binding sites, binding the primary antibody (1:5000 HSP), washing unbound primary antibody, binding the anti-IgG conjugate, washing to remove unbound conjugate and detection by chemiluminescence. Protein immunoblots were scanned by 690 Bio-Rad Densitometer using the Multi-Analyst program (Bio-Rad). 

Statistical analysis 

To test the significance of the data resulting from the optical densitometry of HSP70 recognition among the 4 experimental groups, an analysis of variance by range ordering (Kruskal-Wallis test) was used. Differences between groups were considered significant at p < 0.05. 

RESULTS 

Western blots analysis 

Expression of HSP70 in heart and liver: The anti-HSP70 monoclonal antibody used in the present investigation reacted only with a single band corresponding to the 70-kDa rat HSP70 protein in all groups (Figs. 1 and 2). Representative determinations of samples obtained from a pair of animals in each group showed an evident differential immunolabel recognition of HSP70 between the samples from four groups (Control, ADR, L-Car, L-Car-ADR) and the two different tissues (cardiac and hepatic). 24 hours after ADR toxic stress as shown in Fig. 1, a differential pattern of HSP70 recognition was evident. Particularly, the difference between Control heart and Control liver samples (lanes 1 and 2) was not as high as the difference between ADR ones, where the liver had apparently twice as much HSP70 as the heart (lanes 3 and 4). As shown in Fig. 2, L-Car heart samples showed apparently lower accumulations of HSP70 than the corresponding liver counterparts (lanes 1 and 2 respectively). In the heart L-Car-ADR group a depressed expression of HSP70 in contrast to the liver was observed (lanes 3 and 4). Lower liver HSP70 recognition in L-Car-ADR than in ADR groups, in contrast to heart (Fig. 1 and 2, lane 3 and 4) was also observed. Densitometric analysis in conditions of linearity with respect to protein concentration of the sample and time exposure of the photographic film corroborated that the liver HSP70 amount was bigger than that of the heart in all the groups studied. Particularly, Control, ADR, L-Car and L-Car-ADR liver samples were 21%, 71%, 20% and 17% more than the amount detected in the heart, respectively.

Ultrastructural analysis 

Cardiac ultrastructural analysis: Micrographs of the free left ventricular wall showed myocardial cells with nucleus of normal appearance in Control group (Fig. 3A) whereas ADR group (Fig. 3B) had nucleus alteration including form and irregular perinuclear cysternae with invaginations of different size. The L-Car group (Fig. 3C) resembled the Control, and the L-Car-ADR group (Fig. 3D) showed a continuous perinuclear cysternae like Control and L-Car, and few lipid drops in the cytoplasm.

Hepatic ultrastructural analysis: Hepatic tissue of the four groups (Fig. 4 A,B,C,D respectively) showed hepatocytes with normal appearance.

DISCUSSION 

A differential level of HSP70 expression between liver and heart of short-term ADR treated female rats was found in the present study. HSP70 is believed to participate in an array of cellular activities, including cytoprotection (22). Exposure of cardiac myocytes to oxidative stress by H2O2 treatment causes post-translational modification in two protein families involved in cytoprotection: the peroxiredoxins and two small heat shock protein family members: alfa Beta-crystallin and HSP25 (31). In ADR cardio toxicity protected by L-Car, it has been suggested that there is a relation between HSP25 cellular content in the short term and cytoprotection expressed in terms of a heart subcellular pathology of less severity, in the long term (26). A redox mechanism may be involved in the heat-shock signal pathway in oxidative stress, where induction of HSP70 protein has been correlated with a marked depletion of intracellular bound thiols and a decrease in lipid peroxidation (32). In astrocytes treated with acetyl-L-Car the induction of heme oxygenase-1 was related to the up-regulation of HSP60 as well as high expression of the redox-sensitive transcription factor Nrf2 in the nuclear fraction of treated cells (33). Acetyl-L-Car activities include acetylation of -NH2 and -OH functional groups in amino acids and N terminal amino acids in proteins; as well as, acting as a molecular chaperone to larger molecules (34). In addiction, a stress-regulated protein, GRP58, a member of thioredoxin superfamily, is a carnitine palmitoyltransferase isoenzyme (35). On the other hand, stress is accompanied by changes in the energy state. As a result, the preferential oxidation of cardiac mitochondrial DNA following acute intoxication with ADR may account for many of the bioenergetic deficits associated with the cardiotoxicity observed in vivo (36). Potencial molecular mechanisms of liver L-Car endogenous biosynthesis might be related to the bioenergetic deficits observed in mitochondria isolated from heart, but no liver (37). A moderate decrease in intracellular ATP correlates with an attenuation in HSF1 in the heart and the restoration of ATP leads to greater activation of HSF1 (38). In this regard, acetil-L-Car acts by stimulating energy metabolism. Futhermore, the redox regulation of mammalian HSF1 is essential for HSP gene activation and protection from stress (39). It is possible that HSP70 plays a chaperone role in the process of ribosome biogenesis. The stabilization of ribosome assembly may have an impact in the preservation of protein synthesis during stress and may be an important component of the general mechanism of cytoprotection mediated by HSPs (40). However, following a stressful condition, HSP70 mRNA and protein are induced in different cell types depending on the severity and the nature of the stimulus (22). In addition, sex, causes differences in drug toxicity in rat, where female Sprague-Dawley hearts have twice as much HSP70 as male hearts, due to upregulation by estrogen (41). Moreover, correspondence between the expression and/or accumulation of different HSPs has been linked to the establishment of a synergic network related to the maintenance of protein stability (42). The proven stimulation capacity of L-Car in relation to increased HSP25 detection in response to ADR (26), could involve other members of the HSP family including HSP70, in both heart and liver tissue. In addition in ADR cardiomyopathy a depressed protein synthesis including HSPs has also been demonstrated (43) in contrast to the hepatic response. The presence of HSPs may prevent the damaging effects of stress by impeding the precipitation of denatured proteins caused by the attack (44). The difference in HSP accumulation may alter the effectiveness of the organs to respond to stress. On the other hand, it has been suggested that stress contributes to the pathogenesis of proteinopathies through the stimulation of protein aggregation (45). This may be linked to our findings concerning the presence of cardioproteinopathies observed in the heart in comparison to their apparent absence in the liver of ADR treated rats (46). HSP70 content may contribute to the biochemical differences which may determine tissue susceptibility. In conclusion, the determination of the greater amount of HSP70 in liver than in heart ADR female treated rats, and its correspondence to the bigger tisular preservation in liver than in heart, may be important for understanding the function of this protein in organ differential damage. However, since the biochemical experiments were performed with a monoclonal antibody that recognized both the constitutive and inducible form of HSP70, further experiments are required using antibodies for each form of HSP70 with respect to the correspondence between the HSP70 induced form and the toxic stress condition. We suggest that L-Car exogenous administration might enhance the relationship between cellular energy state and activation of heat shock response by the promotion of HSP70 in a cellular-type manner. 

ACKNOWLEDGEMENTS 

This study was supported by Consejo de Desarrollo Científico y Humanístico (PG 09-00-5676-2004) of the Universidad Central de Venezuela and Laboratorios ELMOR S.A. The authors are grateful to Prof. Mark Gregson for his help with English and to Marianela Rodriguez for her help with ultrastructural analysis. 

REFERENCES 

1. Doroshow JH, Locker GY, Myers CE. Experimental animals model of ADRiamycin cardiotoxicity. Cancer Treat Rep 1979; 63:855-860.        [ Links ]

2. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Eng J Med 1991; 324:843-845.        [ Links ]

3. Phillips FS, Gilladoga A, Marquardt H, Sternberg SS, Vidal PM. Some observations of the toxicity of ADRiamycin (NSC-123127). Cancer Chemother Rep 1975; 6:77-181.        [ Links ]

4. Doroshow JH. Effect of Anthracycline Antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43:460-472.        [ Links ]

5. Singal PK, Segstro RJ, Singh RP, Kutryk MJ. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1985; 1:139-147.        [ Links ]

6. Singal PK, Pierce GN. Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 1986; 250:H419-25.        [ Links ]

7. Singal PK, Deally CM, Weinberg LE. Subcellular Effects of Adriamycin in the heart: A concise Review. J Mol Cell Cardiol 1987; 19:817-828.        [ Links ]

8. Iwamoto Y, Hansen IL, Porter TH. Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase by adriamycin and other quinones having antitumor activity. Biochem Biophys Res Commun 1974; 58:633-638.        [ Links ]

9. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65:128-135.        [ Links ]

10. Odom AL, Hatwig CA, Stanley JS, Benson AM. Biochemical determinants of ADRiamycin toxicity in mouse liver, heart and intestine. Biochem Pharmacol 1992; 43:831-836.        [ Links ]

11. Das DK, Maulik N, Engelman RM, Rousou JA, Deaton D, Flack JE. Signal Transduction pathway leading to hsp 27 and hsp70 gene expression during myocardial adaptation to stress. Annals NY Acad Sci 1999; 874:129-137.        [ Links ]

12. Knowlton AA, Kapadia S, Torre-Amione G, Durand JB, Bies R, Young J, Mann DL. Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol 1998; 30: 811-818.        [ Links ]

13. Jayakumar J, Susuki K, Khan M, Smolenski RT, Farrell A, Latif N, Raisky O, Abunasra H, Sammut IA, Murtuza B, Amrani M, Yacoub MH. Gene therapy for myocardial protection: transfection of donor hearts with heat shock protein 70 gene protects cardiac function against ischemia-reperfusion injury. Circulation 2000; 102:302-306.        [ Links ]

14. Karlseder J, Wissing D, Holzer G, Orel L, Sliutz G, Auer H, Jaattela M, Simon MM. Hsp70 overexpression mediates the escape of a doxorubicin-induced G2 cell cycle arrest. Biochem Biophys Res Commun 1996; 220:153-159.        [ Links ]

15. Kawana K, Miyamoto Y, Tanonaka K, Han-no Y, Yoshida H, Takahashi M, Takeo S. Cytoprotective mechanism of heat shock protein 70 against hypoxia/ reoxygenation injury. J Mol Cell Cardiol 2000; 32:2229-2237.        [ Links ]

16. Martin JL, Hickey E, Weber LA, Dillmann WH, Mestril R. Influence of phosphorylation and oligomerization on the protective role of the small heat shock protein 27 in rat adult cardiomyocytes. Gene Expr 1999; 7:349-355.        [ Links ]

17. Okubo S, Wildner O, Shah MR, Chelliah JC, Hess ML, Kukreja RC. Gene transfer of heat shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in the rabbit heart. Circulation 2001; 103: 877-881.        [ Links ]

18. Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B. The chaperone function of hsp70 is required for protection against stress-induced. Mol Cell Biol 2000; 19:7146-7159.        [ Links ]

19. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M, Weber E, Multhoff G, Rohde M, Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med. 2004; 200:425-435.        [ Links ]

20. Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 1998; 17:6124-6134.        [ Links ]

21. Leonardi R, Pannone G, Magro G, Kudo Y, Takata T, Lo Muzio L. Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and scamous cell carcinoma. Oncol Rep 2002; 9:261-266.        [ Links ]

22. Rajdev S, Sharp FR. Stress protein as molecular markers of neurotoxicity. Toxicol Pathol 2000; 28:105-112.        [ Links ]

23. Beck SC, Paidas CN, Tan H, Yang Jay, De Maio A. Depressed expression of the inducible form of hsp70 (hsp70) in brain and heart after in vivo heat shock. Am J Physiol 1995; 269:R608-R613.        [ Links ]

24. Bieber LL. Carnitine. Ann Rev Biochem 1998; 57:261-283.        [ Links ]

25. Alvarez M, Malécot CO, Gannier F, Lignon JM. Antimony-induced cardiomyopathy in guinea-pig and protection by L-carnitine. B J Pharmacol 2005; 144:17-27.        [ Links ]

26. Strauss M, Anselmi G, Hermoso T, Tejero F. Carnitine promotes heat shock protein synthesis in adriamycin-induced cardiomyopathy in a neonatal rat experimental model. J Mol Cell Cardiol 1998; 30: 2319-2325.        [ Links ]

27. Pauly DF, Pepine CJ. The Role of Carnitine in myocardial dysfunction. Am J Kidney Dis 2003; 41:S35-43.        [ Links ]

28. Sayed-Ahmed MM, Salman TM, Gaballal HE, Abou El-Naga SA, Nicolai R, Calvani M. Propionil L-carnitine as protector against adriamycin induced. cardiomyopathy 2001; 43:513-520.        [ Links ]

29. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of protein from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4354.        [ Links ]

30. Laemmli UK. Cleavege of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.        [ Links ]

31. Cullingford TE, Wait R, Clerk A, Sugden PH. Effects of oxidative stress on the cardiac myocyte proteome: modifications to peroxiredoxins and small heat shock proteins. J Mol Cell Cardiol 2006; 40:157-162.        [ Links ]

32. Calabrese V, Renis M, Calderone A, Russo A, Barcelllona ML, Rizza V. Stress protein and SH-groups in oxidant-induced cell damage alter acute etanol administration in rat. Free Radic Biol Med 1996; 20:391-397.        [ Links ]

33. Calabrese V, Ravagna A, Colombrita C, Scapagnini G, Guagliano E, Calvani M, Butterfield DA, Giuffrida Stella AM. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res. 2005; 79:509-521.        [ Links ]

34. Pettegrew JW, Levine J, McClure RJ. Acetyl-L-Carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry 2000; 5:616-632.        [ Links ]

35. Murthy MSR, Pande SV. A stress-regulated protein, GRP58, a member of thioredoxin superfamily, is a carnitine palmitoyltransferase isoenzyme. Biochem. J 1994; 304:31-34.        [ Links ]

36. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta 1997; 1321:101-106.        [ Links ]

37. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992; 256:628-632.        [ Links ]

38. Chang J, Knowlton AA, Xu F, Wasser JS. Activation of the heat shock response: relationship to energy metabolites. A P-(31) P NMR study in rat hearts. Am J Physiol Heart Circ Physiol 2001; 280:H426-433.        [ Links ]

39. Ahn SG, Thiele DJ. Redox regulation of mammalian heat shoack factor 1 is essential for Hsp gene activation and protection from stress. Genes and Development 2003; 17:516-528.        [ Links ]

40. Cornivelli L, Zeidan Q, De Maio A. HSP70 Interacts with ribosomal subunits of thermotolerant cells. Shock 2003; 20:320-325.        [ Links ]

41. Voss MR, Stallone JN, Li M, Cornelussen RN, Knuefermann P, Knowlton AA. Gender differences in the expression of heat shock proteins: the effect of estrogen. Am J Physiol Heart Circ Physiol 2003; 285: H687-92.        [ Links ]

42. Coronato S, Di Girolano W, Salas M, Spinelli O, Laguens G. Biología de las proteínas del choque térmico. Medicina (Buenos Aires) 1999; 59:477-486.        [ Links ]

43. Löw-Friedrich I, von Bredow F, Schoeppe W. In vitro studies of the cardiotoxicity of chemo therapeutics. Chemotherapy 1990; 36:416-421.        [ Links ]

44. De Maio A. Heat shock protein, oxygen radicals, and apoptosis: The conflict between protection and destruction. Crit Care Med 2000; 28:1679-1681.        [ Links ]

45. Macario AJ, Coway de Macario E. Stress and Molecular Chaperones disease. Int J Clin Lab Res 2000; 30:49-66.        [ Links ]

46. Strauss M, Anselmi G. Is adriamycin cardiomyopathy a proteinopathy subcellular dense content and depressed accumulation of protected protein. In: Microscopy Methods in Pathology, Proceedings of the 15 th International Congress on Electron Microscopy, Durban, South Africa, 1-6 September 2002.        [ Links ]

Corresponding author: Mirian Strauss. Sección de Biología Celular, Instituto de Medicina Tropical, Universidad Central de Venezuela. Apartado Postal 47019, Caracas 1041-A, Venezuela. Phone: +58-212-6053650, Fax: +58-212-2434685. E-mail: mstraussve@yahoo.com